Supernus Pharmaceuticals, Inc.SUPNNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-300.53%
↓ 171% below average
Average (39q)
423.16%
Historical baseline
Range
High:15961.29%
Low:-1822.50%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -300.53% |
| Q2 2025 | 290.23% |
| Q1 2025 | -177.16% |
| Q4 2024 | -60.18% |
| Q3 2024 | 93.30% |
| Q2 2024 | 15961.29% |
| Q1 2024 | -89.45% |
| Q4 2023 | 107.35% |
| Q3 2023 | -1822.50% |
| Q2 2023 | -104.90% |
| Q1 2023 | -33.49% |
| Q4 2022 | 1356.89% |
| Q3 2022 | -77.76% |
| Q2 2022 | -69.30% |
| Q1 2022 | 948.98% |
| Q4 2021 | -88.67% |
| Q3 2021 | -9.12% |
| Q2 2021 | 316.68% |
| Q1 2021 | -81.49% |
| Q4 2020 | -23.07% |
| Q3 2020 | 15.37% |
| Q2 2020 | 61.11% |
| Q1 2020 | -35.05% |
| Q4 2019 | 14.79% |
| Q3 2019 | -11.82% |
| Q2 2019 | 78.45% |
| Q1 2019 | -29.17% |
| Q4 2018 | -7.56% |
| Q3 2018 | -8.87% |
| Q2 2018 | 16.64% |
| Q1 2018 | 92.94% |
| Q4 2017 | -14.43% |
| Q3 2017 | -8.10% |
| Q2 2017 | 68.67% |
| Q1 2017 | -28.09% |
| Q4 2016 | -76.84% |
| Q3 2016 | 503.12% |
| Q2 2016 | 112.46% |
| Q1 2016 | -29.78% |
| Q4 2015 | 75.46% |